N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n'-(5-methyl-3-isoxazolyl)urea salt in crystalline form
AssigneeKirin Beer Kabushiki Kaisha
InventorsNaoki Matsunaga, Satoshi Yoshida, Ayako Yoshino, Tatsuo Nakajima
Life of this patent
Estimating the term…
Abstract
The present invention provides a crystal of a pharmaceutically acceptable salt of N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N′-(5-methyl-3-isoxazolyl) urea. This crystal of salt is usable for the therapy of a disease selected from the group consisting of tumors, diabetic retinopathy, chronic rheumatism, psoriasis, atherosclerosis, Kaposi's sarcoma, and exudation type age-related maculopathy, and has characteristics suitable for applications of oral pharmaceutical preparations.
Claims31
A crystal of a hydrochloride of N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N′-(5-methyl-3-isoxazolyl)urea, wherein said hydrochloride is a hydrochloric acid monoadduct and a monohydrate.
2-12. (canceled)
24-50. (canceled)
A process for producing a crystal of hydrochloride of N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N′-(5-methyl-3-isoxazolyl)urea, wherein said hydrochloride is a hydrochloric acid monoadduct and a monohydrate, said process comprising the steps of:
- adding hydrochloric acid and ethanol to a solution of N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N′-(5-methyl-3-isoxazolyl)urea in an aprotic polar solvent;
- and precipitating crystals from the solution.
56-67. (canceled)
72-73. (canceled)
Dependencies are inferred from the claim text.